BIOGENERA SpA has officially signed an agreement with CVBF (Consortium for Biological and Pharmacological Evaluations) to monitor and execute the phase I clinical trial of the new drug BGA002, intended for the treatment of aggressive pediatric cancers associated with alterations in the MYCN tumor gene.

Funding from the European Community (Horizon program) has been approved for the biomedical research program called ARACHNID (Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD), which will be carried out in collaboration between BIOGENERA’s R&D team and the research group of Prof. Elisa Cimetta of the University of Padua.